RECRUITING

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Conditions

KSHV Inflammatory Cytokine Syndrome (KICS)KSHV HHV-8 KICS HIV Cytokines

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Background: \- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms. They include fever, weight loss, and fluid in the legs or abdomen. People with KICS may also be at risk of getting other cancers associated with KSHV. These cancers include Kaposi sarcoma and lymphoma. Because KICS is a newly identified disease, more information is needed on how the disease works and what can be done to treat it. Objectives: \- To collect genetic and medical information from people with KSHV inflammatory cytokine syndrome. Eligibility: \- Individuals at least 18 years of age who have Kaposi sarcoma herpes virus and symptoms that resemble those caused by KICS. Design: * Participants will have regular study visits. The schedule will be determined by the study researchers. * Participants will provide a complete medical history and have a full physical exam. Blood and urine samples will be collected as well. * People with KICS that requires treatment may get new experimental treatments. These treatments may include antiviral drugs and chemotherapy drugs, depending on the nature of the disease. * Participants will have imaging studies, such as chest x-rays and computed tomography scans, to study the tumors. * Bone marrow and lymph node biopsies may be done to collect tissue samples for study. * Participants who have Kaposi sarcoma will have photographs taken of their lesions....

Official Title

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

Quick Facts

Study Start:2011-09-08

Study Completion:2028-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT01419561

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Age greater than or equal to18 Years. * Any HIV status. * At least two manifestations drawn from at least two of the categories (clinical symptoms, laboratory abnormalities and/or radiographic abnormalities), which are at least possibly attributable to KICS and are not readily explicable from known medical conditions in the participant: * Clinical symptoms (each at least grade 1 by CTCAE definitions) * Fever (\>38 degrees C), chills or rigors * Fatigue or lethargy * Cachexia or edema * Cough, dyspnea, airway hyperreactivity, or nasal inflammation * Nausea, anorexia, abdominal pain or altered bowel habit * Athralgia or myalgia * Altered mental state * Neuropathy with or without pain * Laboratory abnormalities * Anemia (hemoglobin\<12.0g/dL) * Thrombocytopenia (platelets\<100,000 cells/microL) * Leukopenia (white cell count\<4,000 cells/microL) * Hypoalbuminemia (albumin\<3.5g/dL) * Hyponatremia (sodium\<135mmol/L) * Coagulopathy (PT or PTT \>1.5 times upper limit of normal) * Radiographic Abnormalities * Pathologic lymphadenopathy (at least five discrete nodes each \>1cm in their longest dimension) * Splenomegaly (\>12 cm in the longest dimension) * Hepatomegaly (\>17cm in the longest dimension) * Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions directly related to lymphatic infiltration by KS * C-reactive protein (CRP) \>3mg/L. * Exposure risk for KSHV infection (including being a first or second generation immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV infection demonstrated by one of: * Molecular evidence of KSHV in whole blood, or KSHV VL levels within circulating PBMCs as determined by the Whitby laboratory * Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA or vIL-6) confirmed in the Laboratory of Pathology (LP), CCR, NCI. * Presence of KS or PEL (KSHV-associated malignancies), confirmed in the LP, CCR, NCI. * Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and after treatment (if received), according to drug requirements. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.	* Pregnancy * Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to HIV, its treatment, or to KICS that would preclude the use of all of the study treatments or the ability to monitor the natural history of KICS untreated. * Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual.

Inclusion Criteria

Exclusion Criteria

* Age greater than or equal to18 Years.
* Any HIV status.
* At least two manifestations drawn from at least two of the categories (clinical symptoms, laboratory abnormalities and/or radiographic abnormalities), which are at least possibly attributable to KICS and are not readily explicable from known medical conditions in the participant:
* Clinical symptoms (each at least grade 1 by CTCAE definitions)
* Fever (\>38 degrees C), chills or rigors
* Fatigue or lethargy
* Cachexia or edema
* Cough, dyspnea, airway hyperreactivity, or nasal inflammation
* Nausea, anorexia, abdominal pain or altered bowel habit
* Athralgia or myalgia
* Altered mental state
* Neuropathy with or without pain
* Laboratory abnormalities
* Anemia (hemoglobin\<12.0g/dL)
* Thrombocytopenia (platelets\<100,000 cells/microL)
* Leukopenia (white cell count\<4,000 cells/microL)
* Hypoalbuminemia (albumin\<3.5g/dL)
* Hyponatremia (sodium\<135mmol/L)
* Coagulopathy (PT or PTT \>1.5 times upper limit of normal)
* Radiographic Abnormalities
* Pathologic lymphadenopathy (at least five discrete nodes each \>1cm in their longest dimension)
* Splenomegaly (\>12 cm in the longest dimension)
* Hepatomegaly (\>17cm in the longest dimension)
* Body cavity effusions not caused by primary effusion lymphoma nor chylous effusions directly related to lymphatic infiltration by KS
* C-reactive protein (CRP) \>3mg/L.
* Exposure risk for KSHV infection (including being a first or second generation immigrant from an endemic area, or male-to-male sexual activity) or evidence of KSHV infection demonstrated by one of:
* Molecular evidence of KSHV in whole blood, or KSHV VL levels within circulating PBMCs as determined by the Whitby laboratory
* Immunohistochemical evidence of KSHV in tissues (for example by staining for LANA or vIL-6) confirmed in the Laboratory of Pathology (LP), CCR, NCI.
* Presence of KS or PEL (KSHV-associated malignancies), confirmed in the LP, CCR, NCI.
* Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and after treatment (if received), according to drug requirements. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.

* Pregnancy
* Any abnormality that would be scored as NCI CTC Grade 4 toxicity that is unrelated to HIV, its treatment, or to KICS that would preclude the use of all of the study treatments or the ability to monitor the natural history of KICS untreated.
* Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual.

Contacts and Locations

Study Contact

Anaida Widell

CONTACT

(240) 760-6074

anaida.widell@nih.gov

Robert Yarchoan, M.D.

CONTACT

(240) 760-6075

robert.yarchoan@nih.gov

Principal Investigator

Robert Yarchoan, M.D.

PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Study Locations (Sites)

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892

United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

Robert Yarchoan, M.D., PRINCIPAL_INVESTIGATOR, National Cancer Institute (NCI)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2011-09-08

Study Completion Date2028-12-31

Study Record Updates

Study Start Date2011-09-08

Study Completion Date2028-12-31

Terms related to this study

Keywords Provided by Researchers

KSHV
KICS
HIV
Cytokines
HHV-8

Additional Relevant MeSH Terms

KSHV Inflammatory Cytokine Syndrome (KICS)
KSHV
HHV-8